VulnerabilityModified
CVE-2022-48224
It is installed with insecure permissions (full write access within Program Files).
HIGH 7.3EPSS 0.22%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.22%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
An issue was discovered in Acuant AcuFill SDK before 10.22.02.03. It is installed with insecure permissions (full write access within Program Files). Standard users can replace files within this directory that get executed with elevated privileges, leading to a complete arbitrary code execution (elevation of privileges).
- CVSS 3.1
- 7.3 HIGHCVSS:3.1/AV:L/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:H
- EPSS
- 0.22% probability · 12th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-427
- Affected
- gbgplc/acuant acufill sdk
- Source
- cve@mitre.org
References
- https://acuant.comNot Applicable
- https://hackandpwn.com/disclosures/CVE-2022-48224.pdfThird Party Advisory
- https://acuant.comNot Applicable
- https://hackandpwn.com/disclosures/CVE-2022-48224.pdfThird Party Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.